Company Quick10K Filing
Bruker
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 158 $7,442
10-Q 2019-11-04 Quarter: 2019-09-30
10-Q 2019-08-09 Quarter: 2019-06-30
10-Q 2019-05-08 Quarter: 2019-03-31
10-K 2019-03-01 Annual: 2018-12-31
10-Q 2018-11-09 Quarter: 2018-09-30
10-Q 2018-08-09 Quarter: 2018-06-30
10-Q 2018-05-10 Quarter: 2018-03-31
10-K 2018-03-16 Annual: 2017-12-31
10-Q 2017-11-09 Quarter: 2017-09-30
10-Q 2017-08-09 Quarter: 2017-06-30
10-Q 2017-05-10 Quarter: 2017-03-31
10-K 2017-03-01 Annual: 2016-12-31
10-Q 2016-11-09 Quarter: 2016-09-30
10-Q 2016-08-05 Quarter: 2016-06-30
10-Q 2016-05-06 Quarter: 2016-03-31
10-K 2016-02-29 Annual: 2015-12-31
10-Q 2015-11-06 Quarter: 2015-09-30
10-Q 2015-08-07 Quarter: 2015-06-30
10-Q 2015-05-08 Quarter: 2015-03-31
10-K 2015-02-27 Annual: 2014-12-31
10-Q 2014-11-07 Quarter: 2014-09-30
10-Q 2014-08-08 Quarter: 2014-06-30
10-Q 2014-05-09 Quarter: 2014-03-31
10-K 2014-02-27 Annual: 2013-12-31
10-Q 2013-11-08 Quarter: 2013-09-30
10-Q 2013-08-08 Quarter: 2013-06-30
10-Q 2013-05-09 Quarter: 2013-03-31
10-K 2013-02-28 Annual: 2012-12-31
10-Q 2012-11-08 Quarter: 2012-09-30
10-Q 2012-08-09 Quarter: 2012-06-30
10-Q 2012-05-09 Quarter: 2012-03-31
10-K 2012-02-29 Annual: 2011-12-31
10-Q 2011-11-09 Quarter: 2011-09-30
10-Q 2011-08-09 Quarter: 2011-06-30
10-Q 2011-05-09 Quarter: 2011-03-31
10-K 2011-03-01 Annual: 2010-12-31
10-Q 2010-11-08 Quarter: 2010-09-30
10-Q 2010-08-09 Quarter: 2010-06-30
10-Q 2010-05-10 Quarter: 2010-03-31
10-K 2010-03-12 Annual: 2009-12-31
8-K 2020-02-18 Earnings, Regulation FD, Other Events, Exhibits
8-K 2020-01-13 Earnings, Regulation FD
8-K 2019-12-11 Enter Agreement, Leave Agreement, Off-BS Arrangement, Exhibits
8-K 2019-10-31 Earnings, Exhibits
8-K 2019-08-01 Earnings, Exhibits
8-K 2019-05-29 Other Events
8-K 2019-05-20 Shareholder Vote
8-K 2019-05-09 Other Events, Exhibits
8-K 2019-05-02 Earnings, Exhibits
8-K 2019-04-25 Other Events
8-K 2019-02-14 Officers, Exhibits
8-K 2019-02-07 Enter Agreement, Earnings, Exhibits
8-K 2018-11-04 Officers
8-K 2018-11-01 Earnings, Exhibits
8-K 2018-08-02 Earnings, Exhibits
8-K 2018-06-06 Officers, Exhibits
8-K 2018-05-21 Shareholder Vote, Other Events
8-K 2018-05-03 Earnings, Exhibits
8-K 2018-03-12 Officers, Exhibits
8-K 2018-02-28 Officers, Exhibits
8-K 2018-02-16 Officers, Exhibits
8-K 2018-02-08 Earnings, Exhibits

Bruker Financials

BRKR Metrics, Comps, Filings

Annual | Quarterly

Business

We are a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Many of our products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. Our products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research. Our technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas and liquid chromatography triple quadrupole mass spectrometry technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, fluorescence optical microscopy, and infrared and Raman molecular spectroscopy technologies. We also develop, manufacture and distribute a range of field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. Our infectious disease portfolio includes DNA test strips and fluorescence-based polymerase chain reaction (PCR) technology for specific infectious disease applications. We also develop, manufacture and market high and low temperature superconducting materials and devices based primarily on metallic low temperature superconductors. Our corporate headquarters are located in Billerica, Massachusetts. We maintain major technical and manufacturing centers in Europe and North America, and have sales offices located throughout the world.

We originally were incorporated in Massachusetts in February 1991, as Bruker Federal Systems Corporation. In February 2000, we reincorporated in Delaware as Bruker Daltonics Inc. In July 2003, we merged with Bruker AXS Inc., and we were the surviving corporation in that merger. In connection with that merger, we changed our name to Bruker BioSciences Corporation and formed two operating subsidiaries, Bruker Daltonics and Bruker AXS. In July 2006, we acquired Bruker Optics Inc. In February 2008, we acquired the Bruker BioSpin group of companies and changed our name to Bruker Corporation.

We have two reportable segments, Bruker Scientific Instruments (BSI), which represented approximately 90% of our revenues during the year ended December 31, 2018, and Bruker Energy & Supercon Technologies (BEST), which represented the remainder of our revenues. Within BSI, we are organized into three operating segments: the Bruker BioSpin Group, the Bruker CALID Group and the Bruker Nano Group. For financial reporting purposes, the Bruker BioSpin, Bruker CALID and Bruker Nano operating segments are aggregated into the BSI reportable segment because each has similar economic characteristics, production processes, service offerings, types and classes of customers, methods of distribution and regulatory environments.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Illumina (ILMN) 53,118 69% 39.9 13% 6,973 2,641 3,404 2,344 938 1,312 52,296
Agilent Technologies (A) 24,928 41% 18.0 10% 8,625 3,878 5,090 2,068 877 1,357 24,451
Mettler Toledo (MTD) 20,814 58% 28.7 21% 2,661 2,157 2,964 1,705 547 760 21,778
Waters (WAT) 14,408 18% 21.0 21% 2,823 2,267 2,406 428 580 702 14,780
PerkinElmer (PKI) 9,598 49% 21.8 4% 6,399 3,692 2,802 1,364 252 529 11,558
Bio-Rad Laboratories (BIO) 9,137 54% 5.7 12% 7,647 2,160 2,289 1,239 905 1,583 8,992
Bruker (BRKR) 7,442 48% 23.7 8% 2,350 1,489 1,972 940 190 323 7,650
Coherent (COHR) 3,303 36% 22.1 6% 2,137 835 1,557 568 126 153 3,383
Accelerate Diagnostics (AXDX) 1,214 41% -17.8 -54% 159 133 7 3 -86 -73 1,298
Pacific Biosciences of California (PACB) 927 30% -8.4 -65% 171 95 79 24 -111 -108 908
Fluidigm (FLDM) 850 27% -13.8 -24% 284 111 120 32 -69 -60 824
Quanterix (QTRX) 818 50% -20.4 -34% 109 35 47 24 -37 -37 752
EyePoint Pharmaceuticals (EYPT) 175 79% -1.9 -108% 91 63 10 8 -98 -92 177
Harvard Bioscience (HBIO) 76 55% 9.1 -0% 166 86 120 67 -0 14 124
HTG Molecular Diagnostics (HTGM) 49 37% -2.2 -49% 35 23 21 8 -17 -15 33
Bionano Genomics (BNGO) 27 19% -1.0 -56% 25 27 11 2 -14 -11 12
Astrotech (ASTC) 16 29% -2.0 -204% 4 1 0 0 -8 -7 14
Precipio (PRPO) 16 4% -0.9 -81% 22 8 5 0 -18 -17 15
Aethlon Medical (AEMD) 7 0% -0.7 -243% 3 2 0 0 -7 -7 5

Balance Sheet ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash6873202673423294
Accounts Receivable283289308293235244319357
Inventory576612590477422440486510
PP&E249284300623231239266271
Assets1,7101,8561,9881,8651,7311,8081,9482,129
Accounts Payable72707576728691104
Long-Term Debt219336354354267412416341
Liabilities1,0891,1501,1421,0991,0051,1221,2231,232
Stockholders' Equity622707846766726686725897
Income Statement ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue1952102192321,3812552781,896
Cost of Revenue107121142150140869953996
Gross Profit752831805763709742813900
R&D177195190174146149163173
SG&A407442438451392390416445
Tax5260435657725364
Net Income9478826010515480181
Cash Flow ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating88133145114229131154240
Cash Investing-69-93-60-202-102-22-30-123
Cash Financing334267-168-27-159-112